The present study explored whether the use of group medication with antibiotics in a Danish pig herd was reduced after vaccination of the pigs against proliferative enteropathy (PE) caused by Lawsonia intracellularis. 7900 pigs originating from a single commercial sow herd were vaccinated against L. intracellularis, whereas 7756 pigs were kept as non-vaccinated controls. The pigs were included batch-wise in the study with every second batch being vaccinated. In the vaccinated batches, the consumption of oxytetracykline to treat PE was reduced by 79%, with a significantly lower number of pigs being treated (P < 0.0001). Vaccination also resulted in a highly significant improvement of average daily weight gain (+ 46 g/day; P = 9.55 × 10 -31 ) and carcase weight (+ 1.25 kg; P = 4.54 × 10 -05 ) as well as a shortened fattening period (-8 days; P = 2.01 × 10 -45 ).

BackgroundPorcine reproductive and respiratory syndrome virus (PRRSV) causes significant animal and economic losses worldwide. The infection is difficult to control and PRRSV elimination at local level requires coordinated intervention among multiple farms. This case study describes a successful elimination of PRRSV from all 12 herds on the Horne Peninsula, Denmark, using a combination of load, close, homogenise (LCH) using PRRSV type 2 modified-live vaccine, optimised pig flow, and’10 Golden Rules’ (10GR) for biosecurity management. To the authors’ knowledge, this is the first successful European PRRSV area elimination project documented in detail. The PRRSV type 2 modified-live vaccine was used as part of the LCH method in breeding herds. Complete or partial depopulation was performed in some infected herds. A simplified biosecurity protocol (10GR) based on the McREBEL™ system of pig flow management, was employed in all herds and at all times throughout the study.ResultsAt study commencement, all herds were infected with PRRSV, and most were actively shedding virus. In just over 18 months, all 12 herds on the Horne Peninsula were confirmed to be PRRSV negative by polymerase chain reaction testing and negative for antibodies against PRRSV by enzyme–linked immunosorbent assay testing. All herds were subsequently obtained ‘Specific Pathogen Free’ status for PRRSV.ConclusionsThis study provides compelling evidence suggesting that an area elimination plan combining LCH with PRRSV type 2 vaccination, optimised pig flow, and 10GR for biosecurity management can effectively eliminate PRRSV from a geographic area. Additionally this study confirms the value of a previously unpublished, simplified alternative to the McREBEL system for controlling PRRSV.Electronic supplementary materialThe online version of this article (doi:10.1186/s13028-016-0270-z) contains supplementary material, which is available to authorized users.

Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is the cause of severe reproductive and respiratory disease in swine worldwide. In Denmark, both PRRSV-1 and PRRSV-2 are circulating and approximately 35% of pig herds are seropositive for PRRSV. In November 2010, a pig herd in the Northern part of Denmark experienced an infection with PRRSV-2 with clinical signs that were much more severe than normally reported from current Danish PRRSV-2 affected herds. Due to the clinical observations of reproductive failure in sows and high mortality in piglets, it was speculated that a new, more pathogenic or vaccine evading PRRSV strain had emerged in Denmark. The overall aim of the present study was to perform a genetic and biological characterization of the virus isolated from the diseased herd. Complete genome sequencing of isolates from this herd revealed that although the case strain had some unique genetic features including a deduced 3 amino acid deletion, it was in overall very similar to the other PRRS-2 viruses circulating in Denmark. In an experimental trial in growing pigs, no overt clinical signs or pathology were observed following intranasal inoculation with the new virus isolate. Virus shedding, acute phase protein responses and serological responses were comparable to those seen after experimental challenge with a Danish PRRSV-2 reference strain isolated in 1997. Vaccination with a commercial modified live PRRSV-2 vaccine had a clear reducing effect on virus shedding, magnitude, and duration of viremia and viral load in the lungs. Overall, the results indicate that the severe disease observed in the field was contributed by additional factors in combination with the PRRS virus infection.

In this study, the efficacy of the commercial modified live PRRSV-1 vaccine “Ingelvac PRRSFLEX® EU” was assessed in weaned piglets experimentally infected with PRRSV strain AUT15-33. Seventy-four weaned piglets were allocated to five groups. Vaccinated (groups 1, 2, and 5) and non-vaccinated piglets (groups 3 and 4), infected with either a low dose (103 TCID50/dose; groups 2 and 4) or a high dose (105 TCID50/dose; groups 1 and 3) of the virus, were compared regarding clinical signs, average daily weight gain (ADG), lung lesions, viral load in serum, oral swabs, and tissue samples. In comparison to vaccinated animals, coughing increased notably in the second week after challenge in non-vaccinated piglets. During the same time period, vaccinated, high-dose-infected piglets showed significantly higher ADG (p < 0.05) than non-vaccinated, high-dose-infected animals. All infected piglets reached approximately the same viremia levels, but vaccinated animals showed both a significantly reduced viral load in oral fluid (p < 0.05) and tissue samples and significantly reduced lung lesions (p < 0.05). In conclusion, vaccination was able to increase ADG, reduce the amount of viral shedding via oral fluids, and reduce the severity of lung lesions and the viral load in tissue samples under experimental conditions.

No abstract